CAS: 13080-74-5
3,7-Dichloro-10,11-dihydro-5H-dibenzo[b,f]azepine
CAS:13080-74-5
Formula:
C14H11Cl2N
Purity:
97%
Color and Shape:
Solid
Molecular weight:
264.1498
Ref: IN-DA01K4XL
1g | 507.00 € | ||
100mg | 99.00 € | ||
250mg | 196.00 € |
Estimated delivery in United States, on Tuesday 7 Jan 2025
Carbamazepine Impurity 5
CAS:13080-74-5
Formula:
C14H11Cl2N
Color and Shape:
White To Off-White Solid
Molecular weight:
264.15
Ref: 4Z-C-1932
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Tuesday 7 Jan 2025
3,7-Dichloro-10,11-dihydro-5H-dibenzo[b,f]azepine
CAS:13080-74-5
Purity:
95%
Molecular weight:
264.15g/mol
Ref: 54-OR83367
1g | 1,295.00 € | ||
50mg | 109.00 € | ||
100mg | 184.00 € | ||
250mg | 396.00 € |
Estimated delivery in United States, on Tuesday 14 Jan 2025
3,7-Dichloro-10,11-dihydro-5H-dibenzo[b,f]azepine
CAS:13080-74-5
Purity:
97%
Molecular weight:
264.1499938964844
Ref: 10-F692349
1g | 723.00 € | ||
100mg | 95.00 € | ||
250mg | 217.00 € |
Estimated delivery in United States, on Wednesday 15 Jan 2025
3,7-Dichloro-10,11-dihydro-5H-dibenzo[b,f]azepine
Controlled ProductCAS:13080-74-5
Applications 3,7-Dichloro-10,11-dihydro-5H-dibenzo[b,f]azepine is an intermediate in the preparation of Dichloroimipramine Hydrochloride (D434845), the analog of …
Formula:
C14H11Cl2N
Color and Shape:
Neat
Molecular weight:
264.15
Ref: TR-D438128
10mg | 94.00 € | ||
50mg | 332.00 € | ||
100mg | 512.00 € |
Estimated delivery in United States, on Tuesday 18 Feb 2025
3,7-Dichloro-10,11-dihydro-5H-dibenzo[b,f]azepine
CAS:13080-74-5
Please enquire for more information about 3,7-Dichloro-10,11-dihydro-5H-dibenzo[b,f]azepine including the price, delivery time and more detailed …
Formula:
C14H11Cl2N
Purity:
Min. 95%
Molecular weight:
264.1 g/mol
Ref: 3D-NAA08074
25mg | Discontinued | Request information | |
50mg | Discontinued | Request information | |
100mg | Discontinued | Request information | |
250mg | Discontinued | Request information | |
500mg | Discontinued | Request information |